Roceso Technologies

Roceso Technologies operates at the intersection of medical devices, robotics, neurorehabilitation, and digital health. Its product portfolio combines a soft robotic hand exoskeleton with biosensing, movement tracking, and remote therapy management: EsoGLOVE™ Pro and EsoGLOVE™ Myo address hand rehabilitation, while CygniSENSE™ Motion and CygniCONNECT™ Platform extend the offering into assessment and telerehabilitation. The company identifies international regulatory registrations or approvals and distribution across more than 30 countries, suggesting a cross-market commercial focus; specific markets are listed on its website, but product-by-product status is not established here.

Roceso Technologies was founded in 2016, establishing a historical base in soft robotic rehabilitation technology. Its described portfolio now covers multiple stages of upper-limb therapy: EsoGLOVE™ Pro assists hand rehabilitation, EsoGLOVE™ Myo adds muscle-activity sensing and biofeedback, CygniSENSE™ Motion tracks movement, and CygniCONNECT™ Platform supports remote monitoring and management. With no disclosed funding rounds, valuation, or recent growth announcements, its pace of expansion and financial trajectory remain difficult to quantify.